[

favipiravir

]
A majority of the children who contract Covid-19 may be asymptomatic or mildly symptomatic.(Reuters)

Covid-19 in children: How to identify symptoms early on and tackle them

Written by Prashasti Singh | Edited by Avik Roy, New Delhi
UPDATED ON MAY 15, 2021 02:37 PM IST
According to the health ministry, there are a few characteristics of the virus in children that their guardians should be on the lookout for.
Tablets of Avigan (generic name : Favipiravir), developed by drug maker Toyama Chemical Co at Fujifilm's headquarters in Tokyo.(REUTERS)
Tablets of Avigan (generic name : Favipiravir), developed by drug maker Toyama Chemical Co at Fujifilm's headquarters in Tokyo.(REUTERS)

Favipiravir helps in mild to moderate Covid-19 cases, reduces treatment time: Study

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Arpan Rai
UPDATED ON NOV 21, 2020 07:48 PM IST
The significant improvement in time taken for clinical cure suggests that favipiravir may be beneficial in mild-to-moderate Covid-19, the study states.
The FAITH study enrolled a total of 158 hospitalised patients with moderate symptoms of Covid-19 in India.(REUTERS File)
The FAITH study enrolled a total of 158 hospitalised patients with moderate symptoms of Covid-19 in India.(REUTERS File)

Combination of antiviral drugs shows ‘no superior outcome’ for Covid treatment: Firm

Hindustan Times, New Delhi | By Rhythma Kaul
PUBLISHED ON OCT 10, 2020 10:04 AM IST
In May, Glenmark had received approval from DCGI to conduct phase 3 clinical trials in the country using a combination of antiviral drugs Favipiravir and Umifenovir as a potential Covid-19 treatment strategy
Favipiravir is not recommended for children and pregnant women.(REUTERS)
Favipiravir is not recommended for children and pregnant women.(REUTERS)

Odisha issues SOP for use of antiviral drug Favipiravir by Covid-19 patients

Hindustan Times, Bhubaneswar | By Debabrata Mohanty | Edited by Sparshita Saxena
UPDATED ON OCT 03, 2020 11:56 PM IST
Favipiravir is an antiviral drug that was developed for the treatment of resistant influenza virus in Japan. In case of Covid-19 patients with mild to moderate symptoms, the medicine has proved to be effective.
Mr. Madhu Ramadugu, Managing Director, Fusion Health Care.(Business Wire India)
Mr. Madhu Ramadugu, Managing Director, Fusion Health Care.(Business Wire India)

Fusion Health Care launches COVID-19 drug Favipiravir and an immunity booster

UPDATED ON AUG 17, 2020 05:17 PM IST
Fusion Health Care has a strong pan-India presence with a field force of 600 employees and an innovative portfolio of Critical Care & Cardio-Diabetes products.
A lab technician wearing a full-face mask and a protective suit holds tablets of investigational coronavirus disease (Covid-19) treatment drug Favipiravir.(REUTERS/ For Representative Purposes Only)
A lab technician wearing a full-face mask and a protective suit holds tablets of investigational coronavirus disease (Covid-19) treatment drug Favipiravir.(REUTERS/ For Representative Purposes Only)

Favipiravir quickens recovery, show trials

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON JUL 23, 2020 01:04 AM IST
One of the principal investigators said that they have observed patients randomised to favipiravir seemed to have a faster clinical cure.
The antiviral oral drug is marketed under the brand name FabiFlu and was formally launched in the country on June 21.(Reuters)
The antiviral oral drug is marketed under the brand name FabiFlu and was formally launched in the country on June 21.(Reuters)

Glenmark Pharma drops price of Covid-19 drug Favipiravir to Rs 75/tablet

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON JUL 13, 2020 09:28 PM IST
The Drugs Controller General of India (DCGI) granted it approval for Covid-19 treatment under emergency use authorisation, which means since there is limited data available on the medicine’s performance on Covid-19 positive cases, doctors prescribing it would have to document the written consent of a patient.
Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.(AP)
Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.(AP)

Glenmark gets India approval for favipiravir as Covid-19 treatment

Bengaluru | By Press Trust of India
PUBLISHED ON JUN 19, 2020 08:25 PM IST
The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.
Finished tablets sit inside an unsealed container during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia.(Bloomberg)
Finished tablets sit inside an unsealed container during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia.(Bloomberg)

Glenmark to study efficacy of two antiviral drugs for treating Covid-19

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON MAY 26, 2020 05:36 PM IST
Favipiravir is an oral antiviral drug approved in Japan since 2014 for treating novel or re-emerging influenza virus infections. Umifenovir is another oral antiviral drug licenced for the treatment and prophylaxis of influenza A and B infections in Russia and China.
Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so, in Mumbai on Tuesday.(ANI)
Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so, in Mumbai on Tuesday.(ANI)

Glenmark begins phase 3 clinical trials of favipiravir

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON MAY 13, 2020 04:58 AM IST
Glenmark Pharmaceuticals Limited will be looking at recruiting patients from hospitals in the red zones of states such as Gujarat, Maharashtra and Delhi where the Covid-19 case load is high.
Covid-19 patients who were given Favipiravir reported quicker recovery with greater signs of lung improvement.(Reuters)
Covid-19 patients who were given Favipiravir reported quicker recovery with greater signs of lung improvement.(Reuters)

Coronavirus: China says Japanese anti-flu agent Favipiravir effective on Covid-19 patients

Hindustan Times, New Delhi | By HT Correspondent
UPDATED ON MAR 19, 2020 12:10 PM IST
An active ingredient called Favipiravir, that goes into Japanese anti-flu medicine called Avigan, was tested on over 300 Covid-19 patients in China.
SHARE
Story Saved